MedTrace Logo

Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis

NCT06451172 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-06-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of GP-asPNA for in vivo treatment of severe antibiotic resistant bacterial keratitis.

Conditions

  • Bacterial Keratitis
  • Antibiotic-resistant Bacteria
  • Infections, Bacterial
  • Corneal Diseases
  • Eye Diseases
  • Vision Disorders
  • Sensation Disorders
  • Blindness
  • Antisense Peptide Nucleic Acid
  • Antibacterial Therapy

Interventions

DRUG

ASO

Anticipated 20 Participants will receive a single group administered via eye drops in the study eye.

Sponsors & Collaborators

  • Soochow University

    collaborator OTHER

  • Eye & ENT Hospital of Fudan University

    lead OTHER

Principal Investigators

  • Jiaxu Hong, M.D., Ph.D · Eye, and ENT Hospital,Shanghai Medical College, Fudan University,Shanghai, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-11
Primary Completion
2024-10-01
Completion
2026-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06451172 on ClinicalTrials.gov